Belatacept

Belatacept
Clinical data
Trade names Nulojix
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a606016
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		 Intravenous
    ATC code
    Legal status
    Legal status
    Identifiers
    ChemSpider
    • none
    UNII
     ☒N☑Y (what is this?)  (verify)

    Belatacept (trade name Nulojix) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant [2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only 2 amino acids.

    Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration on June 15, 2011.[3]

    References

    1. ↑ "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
    2. ↑ "Belatacept and Long-Term Outcomes in Kidney Transplantation | NEJM". Retrieved 2018-02-06.
    3. ↑ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.